Sign in or create an account to add this stock to your watchlist.
About Agenus (NASDAQ:AGEN)
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400
Debt
Debt-to-Equity Ratio-0.11
Current Ratio2.16
Quick Ratio2.16
Price-To-Earnings
Trailing P/E Ratio-2.82
Forward P/E Ratio-2.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.88 million
Price / Sales8.42
Cash FlowN/A
Price / CashN/A
Book Value($1.09) per share
Price / Book-3.18
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-120,690,000.00
Net Margins-281.49%
Return on EquityN/A
Return on Assets-98.89%
Miscellaneous
Employees255
Outstanding Shares104,000,000
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) issued its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.14. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 equities research analysts have issued 1 year target prices for Agenus' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Agenus' share price to reach $7.00 in the next year. View Analyst Ratings for Agenus.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Solid Biosciences (SLDB), Novavax (NVAX), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), CASI Pharmaceuticals (CASI) and Fate Therapeutics (FATE).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen Ph.D., Founder, Exec. Chairman & CEO (Age 65)
- Ms. Christine M. Klaskin, VP of Fin. (Age 52)
- Ms. Karen Higgins Valentine, Chief Legal Officer & Gen. Counsel (Age 46)
- Mr. Ozer Baysal, Chief Commercial Officer & Head of HR (Age 62)
- Dr. Robert B. Stein Ph.D., M.D., Sr. R&D Advisor (Age 67)
Has Agenus been receiving favorable news coverage?
Media stories about AGEN stock have trended positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agenus earned a media sentiment score of 0.42 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Agenus' major shareholders?
Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.75%), Point72 Asset Management L.P. (3.34%), Artal Group S.A. (2.64%), Northern Trust Corp (0.93%), Millennium Management LLC (0.91%) and venBio Select Advisor LLC (0.68%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen, Karen Valentine and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.
Which major investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Millennium Management LLC, Candriam Luxembourg S.C.A. and Chicago Equity Partners LLC. Company insiders that have sold Agenus company stock in the last year include Alex Duncan, Christine M Klaskin and Karen Valentine. View Insider Buying and Selling for Agenus.
Which major investors are buying Agenus stock?
AGEN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Artal Group S.A., UBS Group AG, BlackRock Inc., Russell Investments Group Ltd., Northern Trust Corp, Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Agenus stock in the last two years include Corp Incyte, Garo H Armen and Ulf Wiinberg. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $3.47.
How big of a company is Agenus?
Agenus has a market capitalization of $361.92 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Agenus (NASDAQ:AGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Agenus in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 101.73%. The high price target for AGEN is $7.00 and the low price target for AGEN is $7.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.50 | 2.67 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $6.00 | $6.3333 | $6.3333 |
| Price Target Upside: | 101.73% upside | 49.25% upside | 57.55% upside | 57.55% upside |
Agenus (NASDAQ:AGEN) Consensus Price Target History
Agenus (NASDAQ:AGEN) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Agenus (NASDAQ:AGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Agenus (NASDAQ AGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 45.61%
Agenus (NASDAQ AGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/12/2017 | Alex Duncan | CTO | Sell | 6,546 | $3.46 | $22,649.16 | 27,572 |  |
| 12/12/2017 | Christine M Klaskin | VP | Sell | 5,610 | $3.46 | $19,410.60 | 69,943 | |
| 12/12/2017 | Karen Valentine | Insider | Sell | 8,358 | $3.46 | $28,918.68 | 109,879 | |
| 10/30/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.55 | $355,000.00 | | |
| 4/12/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.35 | $335,000.00 | 1,389,021 | |
| 2/14/2017 | Corp Incyte | Major Shareholder | Buy | 10,000,000 | $6.00 | $60,000,000.00 | 17,763,968 | |
| 9/6/2016 | Ulf Wiinberg | Director | Buy | 30,000 | $6.29 | $188,700.00 | 30,000 | |
| 5/9/2016 | Garo H Armen | CEO | Buy | 100,000 | $3.18 | $318,000.00 | 1,346,026 | |
| 5/5/2016 | Ozer Baysal | Insider | Buy | 2,250 | $3.10 | $6,975.00 | 33,538 | |
| 3/7/2016 | Garo H Armen | CEO | Buy | 200,000 | $4.03 | $806,000.00 | 1,251,228 | |
| 12/29/2015 | Garo H. Armen | CEO | Sell | 219,576 | $4.59 | $1,007,853.84 | 1,051,228 | |
| 12/28/2015 | Garo H. Armen | CEO | Sell | 134,352 | $4.60 | $618,019.20 | 1,051,228 | |
| 9/25/2015 | Charles Evan Ballantyne | CFO | Buy | 10,000 | $5.05 | $50,500.00 | 10,000 | |
| 9/25/2015 | Garo H Armen | CEO | Buy | 100,000 | $5.03 | $503,000.00 | 1,409,607 | |
| 4/29/2015 | Shahzad Malik | Director | Sell | 1,107,377 | $7.11 | $7,873,450.47 | | |
| 1/9/2015 | Qvt Associates Gp Llc | Major Shareholder | Sell | 2,343,630 | $5.31 | $12,444,675.30 | | |
| 1/23/2014 | Karen Valentine | VP | Sell | 2,850 | $3.50 | $9,975.00 | 51,534 | |
(Data available from 1/1/2013 forward)
Agenus (NASDAQ AGEN) News Headlines
| Source: |
|
Agenus (NASDAQ:AGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Agenus (NASDAQ:AGEN) Income Statement, Balance Sheet and Cash Flow Statement
Agenus (NASDAQ AGEN) Stock Chart for Friday, May, 25, 2018
Loading chart…
